Kairos Pharma, LTD.
Kairos Pharma is a clinical-stage biopharmaceutical company developing cancer therapies intended to address immune suppression and resistance to drug treatment. Its seven-drug portfolio includes five candidates developed by Kairos, plus two therapeutic agents from its Enviro Therapeutics subsidiary. The candidates include small molecules, peptides, antibodies and an activated T cell therapy for cancers including prostate, lung, breast and brain cancer. ENV 105 is being tested in Phase 1 and Phase 2 trials, while other candidates are in preclinical development or clinical testing. Kairos makes money through licensing and commercialization of its drug technologies and products, including potential partnerships and sublicensing. The company licenses proprietary technologies from Cedars-Sinai Medical Center. Its operations are conducted virtually, apart from clinical trials at third-party facilities. Kairos is based in Los Angeles, California.
No SEC Form 4 filings for $KAPA in the last 30 days.
See all $KAPA insider activity →Kairos Pharma amended its equity line of credit agreement with Helena, setting the purchase price at 97% of daily VWAP, shortening the pricing period to one day, and extending the option to use the ELOC through 2028.
Kairos Pharma, LTD. (KAPA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1
Kairos Pharma (KAPA) reported positive interim results from a Phase 2 trial of ENV-105 plus apalutamide in metastatic castration-resistant prostate cancer, showing a median progression-free survival of 17.7 months compared to 2 months with apalutamide alone. The trial will now focus on first-line therapy after enzalutamide. ENV-105 targets CD105, a protein linked to treatment resistance. The company is presenting these findings at the Cancer R&D 2026 conference.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning KAPA (Kairos Pharma, LTD.). Coverage has skewed bullish: 3 bullish, 1 neutral, and 0 bearish.
Recent KAPA coverage spans corporate actions, financial news and technology.
The ELOC terms are more favorable and longer-dated, potentially reducing near-term dilution risk while preserving financing optionality.
Without the agreement details, the market impact is uncertain, but the filing signals a potentially material corporate development.
Positive interim PFS readout materially improves the perceived efficacy of ENV-105 in combination therapy, supporting higher probability of continued development and future regulatory discussions.
Positive Phase 2 interim results are likely to lift the stock as investors price in potential later-stage success.
Positive trial data is likely to lift KAPA shares as investors price in a potential breakthrough therapy.
AlphAI scores every news story that mentions KAPA with an AI model for sentiment and relevance, and aggregates insider trades from Kairos Pharma, LTD.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Kairos Pharma amended its equity line of credit agreement with Helena, setting the purchase price at 97% of daily VWAP, shortening the pricing period to one day, and extending the option to use the ELOC through 2028.
3 min readKairos Pharma, LTD. (KAPA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1
2 min readKairos Pharma (KAPA) reported positive interim results from a Phase 2 trial of ENV-105 plus apalutamide in metastatic castration-resistant prostate cancer, showing a median progression-free survival of 17.7 months compared to 2 months with apalutamide alone. The trial will now focus on first-line therapy after enzalutamide. ENV-105 targets CD105, a protein linked to treatment resistance. The company is presenting these findings at the Cancer R&D 2026 conference.
4 min readKairos Pharma reported Phase 2 interim data showing median progression-free survival of 17.7 months for ENV-105 plus apalutamide vs 2 months for apalutamide alone (P=0.0008). The trial protocol was modified to enroll patients earlier and expand the eligible population, with trial completion targeted for Q4 2027. ENV-105 is a CD105 antibody aimed at reversing drug resistance.
1 min readKairos Pharma, LTD. (KAPA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer LOS ANGELES — October 6, 2026 — Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company addressin
2 min readKairos Pharma (KAPA) announced a 1-for-7 reverse stock split effective September 1, 2026. The company is developing several cancer treatments, with key updates expected in Q3 2026. KAPA's stock has hit a 52-week low, trading at $0.22, down 21.46%.
2 min readKairos Pharma, LTD. (KAPA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 NOTE: Certain identified information has been excluded from this exhibit and replaced with [***] because it is both (i) not material and (ii) the type of information the Company treats as private or confidential. Agreement for the Support
2 min readKairos Pharma (NYSE:KAPA) shares rose 22.64% to $0.39 in after-hours after the company reported positive interim Phase 1 safety data for ENV-105. Kairos said none of 13 treated patients had serious adverse events. ENV-105 is being tested with AstraZeneca’s Tagrisso in EGFR-mutated NSCLC and in Phase 2 for castrate-resistant prostate cancer.
6 min readKairos Pharma, LTD. (KAPA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001962011 0001962011 2026-06-29 2026-06-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of repor
3 min readENV-105 shows no Grade 3 or 4 toxicities in the early Phase 2 mCRPC trial. Kairos Pharma stock volume soars to 221 million vs. 874K average after safety data release. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On Kairos Pharma, Ltd.
2 min read
